Department of Health
Latest recommendation updates
- ATAGI recommendations on use of Novavax vaccine for adolescents aged 12-17 years
Recent ATAGI considerations
On Wednesday 24 August 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 22 August, 63 million doses of COVID-19 vaccines have been administered in Australia.
Novavax COVID-19 vaccination for children aged 12-17 years
On 28 July 2022 the Therapeutic Goods Administration (TGA) provisionally approved Nuvaxovid (Novavax) COVID-19 vaccine (Biocelect Pty Ltd/Novavax Inc) for use in adolescents aged 12-17 years.
ATAGI has evaluated data on immunogenicity, efficacy, safety, and in international settings to make recommendations on the use of Novavax COVID-19 vaccine in this age group.
/Media Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
